Drug treatment of COVID-19 infection
G Lui, G Guaraldi - Current opinion in pulmonary medicine, 2023 - journals.lww.com
Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …
[HTML][HTML] Efficacy of Molnupiravir for the treatment of mild or moderate COVID-19 in adults: a meta-analysis
The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …
Efficacy and safety of 5-day oral Ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial
H Yotsuyanagi, N Ohmagari, Y Doi, M Yamato… - JAMA network …, 2024 - jamanetwork.com
Importance Treatment options for COVID-19 are warranted irrespective of the presence of
risk factors for severe disease. Objective To assess the efficacy and safety of ensitrelvir in …
risk factors for severe disease. Objective To assess the efficacy and safety of ensitrelvir in …
Impact of early SARS-CoV-2 antiviral therapy on disease progression
Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to
prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r …
prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r …
Molnupiravir and nirmatrelvir/ritonavir: tolerability, safety, and adherence in a retrospective cohort study
Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …
Association between Guillain-Barré syndrome and COVID-19 infection and vaccination: a population-based nested case-control study
H Bishara, A Arbel, O Barnett-Griness, S Bloch… - Neurology, 2023 - AAN Enterprises
Background and Objectives Existing data regarding occurrence of Guillain-Barré syndrome
(GBS) after coronavirus disease 2019 (COVID-19) infection and vaccination are …
(GBS) after coronavirus disease 2019 (COVID-19) infection and vaccination are …
N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody
A Zibat, X Zhang, A Dickmanns, KM Stegmann… - Iscience, 2023 - cell.com
Summary N4-hydroxycytidine (NHC), the active compound of the drug Molnupiravir, is
incorporated into SARS-CoV-2 RNA, causing false base pairing. The desired result is an" …
incorporated into SARS-CoV-2 RNA, causing false base pairing. The desired result is an" …
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents
CA Gentry, P Nguyen, SK Thind, G Kurdgelashvili… - Journal of infection, 2023 - Elsevier
Objectives Molnupiravir and nirmatrelvir/ritonavir each became available in the United
States (US) through the Food and Drug Administration (FDA) emergency use authorization …
States (US) through the Food and Drug Administration (FDA) emergency use authorization …
Real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 in adult patients during the dominance of the Omicron variant: a meta …
C Huang, TL Lu, L Lin - Antibiotics, 2023 - mdpi.com
Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
[HTML][HTML] A sensitive UPLC-MS/MS method for the simultaneous assay and trace level genotoxic impurities quantification of SARS-CoV-2 inhibitor-Molnupiravir in its …
S Nakka, SK Muchakayala, SBM Surya - Results in Chemistry, 2023 - Elsevier
Two potential genotoxic impurities were identified (PGTIs)-viz. 4-amino-1-((2R, 3R, 4S, 5R)-
3, 4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl) pyrimidin-2 (1H)-one (PGTI-1), and 1 …
3, 4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl) pyrimidin-2 (1H)-one (PGTI-1), and 1 …